Document is current
Any future updates will be listed below
-
Authors
Seblani, M.
Zannikou, M.
Duffy, J. T.
Joshi, T.
Levine, R. N.
Thakur, A.
Puigdelloses-Vallcorba, M.
Horbinski, C. M.
Miska, J.
Hambardzumyan, D.
Becher, O. J.
Balyasnikova, Irina V.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P50CA221747, P50CA221747)
National Institute of Neurological Disorders and Stroke (R01NS106379; R01NS122395)
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 26 March 2025
First Online: 2 April 2025
Declarations
:
: Human tumor samples were initially obtained under Institutional Review Board approved protocol (#IRB 2019–3164) per Ann and Robert H. Lurie Children’s Hospital of Chicago. All animal studies were approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC).
: N/A.
: Irina Balyasnikova is an inventor of a single-chain antibody targeting IL13RA2 and the CAR construct used in this study.
